Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generics With Poor Bioavailability May Not Use 505(b)(2) "Paper" NDA

Executive Summary

Generic drug applicants may not use the paper NDA 505(b)(2) mechanism of approval for products that have a reduced rate of absorption compared to the innovator, FDA said in its "Guidance for Industry: Applications Covered by Section 505(b)(2)."

You may also be interested in...



Pfizer Norvasc Challenges: Mylan ANDA, Dr. Reddy’s 505(b)(2)

Pfizer's Norvasc patent suit against Mylan could still delay the launch of Mylan's generic amlodipine, despite the lack of a 30-month stay

Pfizer Norvasc Challenges: Mylan ANDA, Dr. Reddy’s 505(b)(2)

Pfizer's Norvasc patent suit against Mylan could still delay the launch of Mylan's generic amlodipine, despite the lack of a 30-month stay

Pfizer, Pharmacia Protest Inclusion Of Drug Innovator Data In "Paper NDAs"

Pfizer and Pharmacia are requesting that FDA revise a draft guidance so that "paper NDAs" approved under section 505(b)(2) of the Waxman/Hatch patent law would not be allowed to rely on non-published studies conducted by the product innovator.

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel